21 Heart Attack Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Heart Attack Studies in Nashville

NCT06080698Recruiting

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy f...

Nashville, TX1,030 participantsJohns Hopkins University

View Study Details

NCT06854458Recruiting

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the h...

Nashville, TX1,000 participantsBrigham and Women's Hospital

View Study Details

NCT05414994Recruiting

Assessment of the Ocular Microbiome in Health and Disease

The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the he...

Nashville, TX500 participantsVanderbilt University Medical Center

View Study Details

NCT07227155Recruiting

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

A prospective, multicenter study that will establish a repository of biospecimens and clinical data from patients undergoing hematopoietic stem cell transplant (HCT) or gene therapy (GT) for treatment...

Nashville, TX375 participantsMedical College of Wisconsin

View Study Details

NCT06370182Recruiting

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use, which is to facilitate the navigation and deplo...

Nashville, TX327 participantsAnaconda Biomed S.L.

View Study Details

NCT06675344Recruiting

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifical...

Nashville, TX160 participantsRobyn T. Domsic, MD, MPH

View Study Details

NCT06239116Recruiting

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment...

Nashville, TX150 participantsRhythm Pharmaceuticals, Inc.

View Study Details

NCT06055439Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

Nashville, TX135 participantsChimeric Therapeutics

View Study Details

NCT06514794Recruiting

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

Nashville, TX125 participantsWugen, Inc.

View Study Details

NCT06950034Recruiting

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no furthe...

Nashville, TX105 participantsSolu Therapeutics, Inc

View Study Details

NCT07469891Recruiting

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk po...

Nashville, TX100 participantsPrelude Therapeutics

View Study Details

NCT04941599Recruiting

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects w...

Nashville, TX72 participantsVanderbilt University Medical Center

View Study Details

NCT05489575Recruiting

CPAP for the Treatment of Supine Hypertension

This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if ...

Nashville, TX59 participantsVanderbilt University Medical Center

View Study Details

NCT05422794Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatm...

Nashville, TX57 participantsNational Cancer Institute (NCI)

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Nashville, TX52 participantsCellectis S.A.

View Study Details

NCT05546580Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat ...

Nashville, TX50 participantsOryzon Genomics S.A.

View Study Details

NCT07225543Recruiting

2-HOBA in Systemic Lupus Erythematosus

This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in pati...

Nashville, TX42 participantsVanderbilt University Medical Center

View Study Details

NCT06034275Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ h...

Nashville, TX36 participantsVincerx Pharma, Inc.

View Study Details

NCT02897063Recruiting

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the vein...

Nashville, TX34 participantsVanderbilt University Medical Center

View Study Details

NCT06525636Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia....

Nashville, TX24 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT05589896Recruiting

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodyspl...

Nashville, TX12 participantsOssium Health, Inc.

View Study Details

About Heart Attack Clinical Trials in Nashville

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 21 heart attack clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 4,445 participants. Research is being sponsored by Johns Hopkins University, Brigham and Women's Hospital, Vanderbilt University Medical Center and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Nashville — FAQ

Are there heart attack clinical trials in Nashville?

Yes, there are 21 heart attack clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 21 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated July 13, 2026 from ClinicalTrials.gov